BlackRock’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,289
| Closed | -$3.48K | – | 5721 |
|
|
2023
Q1 | $3.48K | Sell |
1,289
-4,815
| -79% | -$18.3K | ﹤0.01% | 5406 |
|
|
2022
Q4 | $24.4K | Sell |
6,104
-79
| -1% | -$483 | ﹤0.01% | 5353 |
|
|
2022
Q3 | $45K | Sell |
6,183
-143
| -2% | -$1.74K | ﹤0.01% | 5381 |
|
|
2022
Q2 | $78K | Buy |
6,326
+5,008
| +380% | +$47K | ﹤0.01% | 5308 |
|
|
2022
Q1 | $22K | Hold |
1,318
| – | – | ﹤0.01% | 5558 |
|
|
2021
Q4 | $85K | Buy |
1,318
+24
| +2% | +$1.4K | ﹤0.01% | 5316 |
|
|
2021
Q3 | $89K | Hold |
1,294
| – | – | ﹤0.01% | 5168 |
|
|
2021
Q2 | $91K | Sell |
1,294
-311
| -19% | -$16.8K | ﹤0.01% | 5078 |
|
|
2021
Q1 | $105K | Hold |
1,605
| – | – | ﹤0.01% | 4835 |
|
|
2020
Q4 | $92K | Buy |
1,605
+1
| +0.1% | +$58 | ﹤0.01% | 4602 |
|
|
2020
Q3 | $95K | Sell |
1,604
-2,047
| -56% | -$183K | ﹤0.01% | 4524 |
|
|
2020
Q2 | $474K | Buy |
3,651
+1,052
| +40% | +$92.9K | ﹤0.01% | 4219 |
|
|
2020
Q1 | $152K | Buy |
2,599
+345
| +15% | +$33.8K | ﹤0.01% | 4277 |
|
|
2019
Q4 | $285K | Buy |
2,254
+20
| +0.9% | +$2.71K | ﹤0.01% | 4270 |
|
|
2019
Q3 | $268K | Sell |
2,234
-21
| -0.9% | -$4.23K | ﹤0.01% | 4284 |
|
|
2019
Q2 | $673K | Buy |
2,255
+1,882
| +505% | +$785K | ﹤0.01% | 4125 |
|
|
2019
Q1 | $168K | Sell |
373
-119
| -24% | -$52.1K | ﹤0.01% | 4270 |
|
|
2018
Q4 | $225K | Buy |
492
+69
| +16% | +$42.8K | ﹤0.01% | 4206 |
|
|
2018
Q3 | $385K | Buy |
423
+17
| +4% | +$11.2K | ﹤0.01% | 4175 |
|
|
2018
Q2 | $238K | Buy |
406
+310
| +323% | +$202K | ﹤0.01% | 4273 |
|
|
2018
Q1 | $63K | Buy |
96
+34
| +55% | +$25.5K | ﹤0.01% | 4413 |
|
|
2017
Q4 | $22K | Buy |
62
+3
| +5% | +$1.15K | ﹤0.01% | 4561 |
|
|
2017
Q3 | $18K | Hold |
59
| – | – | ﹤0.01% | 4621 |
|
|
2017
Q2 | $29K | Buy |
59
+47
| +392% | +$35.6K | ﹤0.01% | 4606 |
|
|
2017
Q1 | $15K | Buy |
+12
| New | +$5.78K | ﹤0.01% | 4661 |
|
|
2016
Q4 | – | Sell |
-22
| Closed | -$9K | – | 3838 |
|
|
2016
Q3 | $9K | Sell |
22
-2
| -8% | -$894 | ﹤0.01% | 3421 |
|
|
2016
Q2 | $12K | Sell |
24
-9
| -27% | -$4.57K | ﹤0.01% | 3387 |
|
|
2016
Q1 | $17K | Sell |
33
-5
| -13% | -$2.79K | ﹤0.01% | 2934 |
|
|
2015
Q4 | $30K | Hold |
38
| – | – | ﹤0.01% | 2367 |
|
|
2015
Q3 | $53K | Hold |
38
| – | – | ﹤0.01% | 1891 |
|
|
2015
Q2 | $77K | Buy |
+38
| New | +$97K | ﹤0.01% | 1860 |
|
BlackRock's HTGM Position: Q2 2023 in Review
BlackRock sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 1,289 shares — an estimated $3.48K sold.
BlackRock first reported a position in HTGM in Q2 2015 and held it in 31 quarters. The position peaked at $673K in Q2 2019. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- BlackRock reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 1,289 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $3.48K.
- BlackRock first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- BlackRock's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $673K in Q2 2019.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.